Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment

Por Dazhi Liu, Michael A. Weintraub, Christine Garcia, Marcus D. Goncalves, Ann Elizabeth Sisk, Alissa Casas, James J. Harding, Stephen Harnicar, Alexander Drilon, Komal Jhaveri, James H. Flory
Publicado em 2022-04-01

A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors

Por James J. Harding, Ignacio Garrido-Laguna, Xiaoying Chen, Cynthia Basu, Afshin Dowlati, Alison Forgie, Andrea T. Hooper, Cris Kamperschroer, Steven I. Max, Steven I. Max, Allison Moreau, Megan Shannon, Gilbert Y. Wong, David S. Hong
Publicado em 2022-04-01